Scienture Holdings (FRA:4E4) Total Liabilities: €11.97 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4E4 Scienture Holdings Inc FRA:4E4
47 GF Score
Price €0.19
GF Value €0.18
! 6 Warning Signs
View Full Analysis

What is Scienture Holdings Total Liabilities?

Scienture Holdings FRA:4E4 -3.06% 47 Total Liabilities is €11.97 Mil as of Mar. 2026. GuruFocus rates FRA:4E4 with a GF Score™ of 47/100 and a GF Value™ of €0.18. The stock has 6 warning signs investors should review.

Scienture Holdings's Total Liabilities for the quarter that ended in Mar. 2026 was €11.97 Mil.

Scienture Holdings's quarterly Total Liabilities declined from Sep. 2025 (€18.88 Mil) to Dec. 2025 (€12.01 Mil) and declined from Dec. 2025 (€12.01 Mil) to Mar. 2026 (€11.97 Mil).

Scienture Holdings's annual Total Liabilities increased from Dec. 2023 (€11.00 Mil) to Dec. 2024 (€24.62 Mil) but then declined from Dec. 2024 (€24.62 Mil) to Dec. 2025 (€12.01 Mil).

Scienture Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for Scienture Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scienture Holdings Total Liabilities Chart

Scienture Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.77 3.18 11.00 24.62 12.01

Scienture Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.31 22.92 18.88 12.01 11.97
FRA:4E4
47GF Score
Scienture Holdings Inc FRA:4E4
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scienture Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Scienture Holdings's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.336+(0+0.244
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+9.426+0+0)
=12.01

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=71.888-59.882
=12.01

Scienture Holdings's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.425+(0+-0.00099999999999945
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+9.548+0+0)
=11.97

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=69.773-57.799
=11.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €11.97 Mil mean?
Scienture Holdings (FRA:4E4) has a Total Liabilities of €11.97 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Scienture Holdings and its competitors.
Is Scienture Holdings' Total Liabilities too high?
Scienture Holdings' current Total Liabilities is €11.97 Mil. Overall, Scienture Holdings has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Total Liabilities compare to WGRX and HEWA?
Scienture Holdings' Total Liabilities of €11.97 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Healthcare Providers & Services company?
A good Total Liabilities depends on the Healthcare Providers & Services industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Scienture Holdings and its competitors. Scienture Holdings's current Total Liabilities is €11.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Scienture Holdings (FRA:4E4) has a current Total Liabilities of €11.97 Mil. The stock's GF Value™ is €0.18, compared to a current price of €0.19 — trading 7.4% above its estimated fair value. The current Total Liabilities is €11.97 Mil. Scienture Holdings' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Scienture Holdings (FRA:4E4), the current Total Liabilities is €11.97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scienture Holdings (FRA:4E4) Overvalued in 2026?

Based on GuruFocus' analysis, Scienture Holdings stock appears to be overvalued. The current stock price of €0.19 is trading 7.4% above its estimated GF Value™ of €0.18.

Key valuation signals for FRA:4E4:

  • Total Liabilities: €11.97 Mil
  • GF Value™: €0.18 vs. price of €0.19 (7.4% above fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the FRA:4E4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scienture Holdings Business Description

Other Exchanges SCNX:USA
Address 20 Austin Boulevard, Commack, NY, USA, 11725
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
47GF Score

Get the complete analysis for FRA:4E4

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price
€0.18
GF Value